Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHA:605199)
China · Delayed Price · Currency is CNY 6.80
+0.16 (2.41%)
Feb 4, 2026, 3:00 PM CST
SHA:605199 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,057 | 1,407 | 1,782 | 1,515 | 1,354 | 1,162 |
Other Revenue | 6.59 | 6.59 | 12.94 | - | - | - |
| 1,064 | 1,414 | 1,795 | 1,515 | 1,354 | 1,162 | |
Revenue Growth (YoY) | -31.37% | -21.26% | 18.49% | 11.91% | 16.54% | -11.04% |
Cost of Revenue | 635.54 | 744.53 | 892.85 | 644.31 | 546.54 | 444.38 |
Gross Profit | 428.14 | 669.02 | 902.33 | 870.74 | 807.25 | 717.33 |
Selling, General & Admin | 459.39 | 730.07 | 734.51 | 654.11 | 612.94 | 541.56 |
Research & Development | 86.01 | 202.08 | 113.66 | 105.66 | 100.43 | 51.66 |
Other Operating Expenses | 11.88 | 11.15 | 16.84 | 13.68 | 17.95 | 13.37 |
Operating Expenses | 569.62 | 947.38 | 880.59 | 773.21 | 734.55 | 616.78 |
Operating Income | -141.49 | -278.36 | 21.74 | 97.52 | 72.7 | 100.55 |
Interest Expense | -42.77 | -31.75 | -18.24 | -18 | -13.87 | -9.1 |
Interest & Investment Income | - | 10.11 | 1.34 | 2.01 | 3.77 | 0.88 |
Currency Exchange Gain (Loss) | - | - | 0 | - | - | - |
Other Non Operating Income (Expenses) | 0.19 | 0.48 | -1.34 | -1.08 | 0.02 | 0.06 |
EBT Excluding Unusual Items | -184.07 | -299.51 | 3.5 | 80.45 | 62.62 | 92.39 |
Gain (Loss) on Sale of Investments | -2.45 | - | -4.43 | -2.06 | -3.66 | -0.49 |
Gain (Loss) on Sale of Assets | -0.18 | 0.04 | -0.08 | -0.55 | -0.47 | -0.21 |
Asset Writedown | -5.79 | -0.86 | - | - | - | - |
Other Unusual Items | 31.12 | 31.17 | 28.04 | 19.38 | 23.18 | 42.7 |
Pretax Income | -161.38 | -269.17 | 27.03 | 97.23 | 81.66 | 134.39 |
Income Tax Expense | 2.39 | 0.35 | 10.05 | 12.49 | 12.11 | 12.89 |
Earnings From Continuing Operations | -163.76 | -269.52 | 16.97 | 84.74 | 69.56 | 121.5 |
Minority Interest in Earnings | -4.36 | -4.94 | -6.12 | 0.94 | 2.58 | - |
Net Income | -168.12 | -274.46 | 10.85 | 85.68 | 72.14 | 121.5 |
Net Income to Common | -168.12 | -274.46 | 10.85 | 85.68 | 72.14 | 121.5 |
Net Income Growth | - | - | -87.33% | 18.77% | -40.63% | 0.97% |
Shares Outstanding (Basic) | 374 | 398 | 362 | 408 | 401 | 380 |
Shares Outstanding (Diluted) | 374 | 398 | 362 | 408 | 401 | 380 |
Shares Change (YoY) | 3.98% | 9.97% | -11.35% | 1.81% | 5.55% | 4.13% |
EPS (Basic) | -0.45 | -0.69 | 0.03 | 0.21 | 0.18 | 0.32 |
EPS (Diluted) | -0.45 | -0.69 | 0.03 | 0.21 | 0.18 | 0.32 |
EPS Growth | - | - | -85.71% | 16.67% | -43.75% | -3.03% |
Free Cash Flow | 29.26 | -305.35 | -460.95 | -153.61 | -35.14 | -56.12 |
Free Cash Flow Per Share | 0.08 | -0.77 | -1.27 | -0.38 | -0.09 | -0.15 |
Dividend Per Share | - | - | 0.125 | - | - | 0.150 |
Dividend Growth | - | - | - | - | - | -33.33% |
Gross Margin | 40.25% | 47.33% | 50.26% | 57.47% | 59.63% | 61.75% |
Operating Margin | -13.30% | -19.69% | 1.21% | 6.44% | 5.37% | 8.65% |
Profit Margin | -15.81% | -19.42% | 0.60% | 5.66% | 5.33% | 10.46% |
Free Cash Flow Margin | 2.75% | -21.60% | -25.68% | -10.14% | -2.60% | -4.83% |
EBITDA | -52.38 | -204.99 | 74.11 | 143.77 | 117.46 | 144.06 |
EBITDA Margin | -4.92% | -14.50% | 4.13% | 9.49% | 8.68% | 12.40% |
D&A For EBITDA | 89.11 | 73.36 | 52.37 | 46.25 | 44.76 | 43.51 |
EBIT | -141.49 | -278.36 | 21.74 | 97.52 | 72.7 | 100.55 |
EBIT Margin | -13.30% | -19.69% | 1.21% | 6.44% | 5.37% | 8.65% |
Effective Tax Rate | - | - | 37.19% | 12.84% | 14.83% | 9.59% |
Revenue as Reported | 1,064 | 1,414 | 1,795 | 1,515 | 1,354 | 1,162 |
Advertising Expenses | - | 446.81 | 443.11 | 452.11 | 426.22 | 401.89 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.